NexImmune

NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke in June 7, 2011 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the publication of an article highlighting the Company's AIM platform as a new immunotherapy approach for viral diseases in Frontiers in Medicine. The article, titled “AIM Platform: A New Immunotherapy Approach for Viral Diseases,” focuses on the ability of AIM nanoparticles, which direct T cell response by mimicking the dendritic cell function, to consistently expand T cell populations with effector memory, central memory and self-renewing stem like memory phenotype directed at peptide-antigens from Epstein-Barr virus (EBV), human T-lymphotropic virus type 1 (HTLV-1) and human papillomavirus (HPV). Furthermore, T cells generated with the AIM platform are highly polyfunctional and display substantial in vitro cytotoxic activity against respective targeted antigens.

NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company's AIM Platform to Treat Viral Diseases

GAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the third quarter of 2022 and announced a change in corporate strategy.

NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update

The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases

NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)

GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET.

NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GENEVA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis' SUREtechnology Platform™

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

GAITHERSBURG, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the second quarter of 2022.

NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers

NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.

NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug

NexImmune appears to be making headway in the company's ongoing battle against HPV-related cancers -- and NEXI stock is heading higher today. The post Why Is NexImmune (NEXI) Stock Up 30% Today?

Why Is NexImmune (NEXI) Stock Up 30% Today?

GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company's first cellular therapy product candidate addressing solid tumors.  NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported financial results for the first quarter of 2022.

NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), Yale and JDRF have begun a two-year project to explore the use of NexImmune's AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The $600,000 grant, funded by JDRF to Yale, is a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).

NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director.

NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors

GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center's (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC). The research will focus on the use of NexImmune's adoptive cell therapy, AIM ACT, in Columbia's patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell carcinoma. Columbia scientists Hiroshi Nakagawa, MD, Associate Professor of Medicine, and Brian Henick, MD, Assistant Professor of Medicine, will lead the research. Dr. Anil Rustgi, Director of HICCC, will join Drs. Nakagawa and Henick in the investigations. HICCC is an NCI designated cancer center that is at the forefront of discovery science, translational medicine, clinical trials, clinical care and community outreach.

NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center

Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology

NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer

Butler National Corporation

Performant Financial

Ricebran Technologies

Tonix Pharmaceuticals Hld

The Dow Jones jumped around 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Executives Buy More Than $1M Of 5 Penny Stocks

Gevo

Helbiz

Hemisphere Media Group

RLX Technology

Follow the money stocks to buy according to insiders The post 5 Top Penny Stocks To Buy According To Insiders In March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Buy According To Insiders In March 2022

LiveOne

NextNav

Red Cat Holdings

STRATA Skin Sciences

The Dow Jones surged around 350 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Insiders Buying These 5 Penny Stocks

NexImmune Inc (NASDAQ: NEXI) and Zephyr AI have announced a strategic partnership focusing on discovering and validating novel targets for new T-cell-mediated therapies in oncology.  The collaboration will combine Zephyr's artificial intelligence and algorithmic.

NexImmune, Zephyr Join Forces For Oncology Target Discovery, Validation

GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr's proprietary artificial intelligence (AI) and algorithmic technology with NexImmune's Artificial Immune Modulation (AIM) nanoparticle technology, the collaboration will seek to identify and validate optimal antigens and antigen cocktails for the development of potential new therapeutics in solid and hematological cancers.

NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health. The collaboration is centered around NexImmune's artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluation.

NexImmune Announces Melanoma Research Collaboration with NYU Langone's Perlmutter Cancer Center

GAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the Barclays 2022 Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. Eastern Time.

NexImmune to Present at the Barclays 2022 Global Healthcare Conference

GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its fourth quarter and full year financial results for the full year 2021.

NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

Ms. Jones, a veteran of the biotechnology and pharmaceutical industries, has served as an Executive Officer of NexImmune since 2017 Ms. Jones, a veteran of the biotechnology and pharmaceutical industries, has served as an Executive Officer of NexImmune since 2017

NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors

GAITHERSBURG, Md., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Rutgers, The State University of New Jersey. The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers. Dr. Steven K. Libutti, Director of Rutgers Cancer Institute of New Jersey, Vice Chancellor of Cancer Programs, Rutgers Biomedical and Health Sciences, and Senior Vice President of Oncology Services, RWJBarnabas Health, will be the principal investigator.

NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets

GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled “Expanding the Possible with Next Generation Cell Therapies” on Friday, January 21, 2022 at 12:00 p.m. Eastern Time.

NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”

News for NexImmune Stock (NEXI)